drug	drug_trade_name	biomarker_type	biomarker_symbol	biomarker_entrez	biomarker_transcript_id	biomarker_aberration_type	biomarker_aberration_value	modifier_type	modifier_symbol	modifier_entrez	modifier_transcript_id	modifier_aberration_type	modifier_aberration_value	indication	evidence	url	evidence_text	qualifying_text	reference	disease	regex_annotate.interproDomain
Cisplatin	unspecified	EMPTY	EMPTY	EMPTY	EMPTY	EMPTY	EMPTY	gene	PRKDC	5591	EMPTY	snv	change	yes	inferred	http://www.ncbi.nlm.nih.gov/pubmed/21679440	Silencing the expression of the catalytic subunit of DNA-PK (DNA-PKcs) increased sensitivity to cisplatin and decreased the appearance of yH2AX after cisplatin treatment. 	SNVs should be loss-of-function and associated with drug sensitivity. However, not all SNVs may result in loss-of-function.	Sand-Dejmek J, Mol Cancer 2011, 10:74	unspecified	
Cisplatin	unspecified	EMPTY	EMPTY	EMPTY	EMPTY	EMPTY	EMPTY	gene	PRKDC	5591	EMPTY	cnv	loss	yes	inferred	http://www.ncbi.nlm.nih.gov/pubmed/21679440	Silencing the expression of the catalytic subunit of DNA-PK (DNA-PKcs) increased sensitivity to cisplatin and decreased the appearance of yH2AX after cisplatin treatment. 	unspecified	Sand-Dejmek J, Mol Cancer 2011, 10:74	unspecified	
